X-press logistics & Courier Services’ Post

New Post: Petri Dish: Vertex kidney drug moves into Ph 3; Fractyl preps for commercialization -At the start of this week, the focus was on Fractyl Health’s first earnings post-IPO and the company’s wide stock swings. Fractyl continued to share news later in the week, including a new executive appointment. Read more about Fractyl and other big biotech news from this week. Source link At the start of this week, the focus was on Fractyl Health’s first earnings post-IPO and the company’s wide stock swings. Fractyl continued to share news later in the week, including a new executive appointment. Read more about Fractyl and other big biotech news from this week. Source link

New Post: Petri Dish: Vertex kidney drug moves into Ph 3; Fractyl preps for commercialization -At the start of this week, the focus was on Fractyl Health’s first earnings post-IPO and the company’s wide stock swings. Fractyl continued to share news later in the week, including a new executive appointment. Read more about Fractyl and other big biotech news from this week. Source link At the start of this week, the focus was on Fractyl Health’s first earnings post-IPO and the company’s wide stock swings. Fractyl continued to share news later in the week, including a new executive appointment. Read more about Fractyl and other big biotech news from this week. Source link

New Post: Petri Dish: Vertex kidney drug moves into Ph 3; Fractyl preps for commercialization -At the start of this week, the focus was on Fractyl Health’s first earnings post-IPO and the company’s wide stock swings. Fractyl continued to share news later in the week, including a new executive appointment. Read more about Fractyl and other big biotech news from this week. Source link At the start of this week, the focus was on Fractyl Health’s first earnings post-IPO and the company’s wide stock swings. Fractyl continued to share news later in the week, including a new executive appointment. Read more about Fractyl and other big biotech news from this week. Source link

🚀 #BiotechTrends Mesoblast Ltd witnesses a dramatic share price surge—up 45.5%—post promising FDA discussions regarding their lead product, remestemcel-L. The #FDA has indicated that clinical data is sufficient to support a Biologics License Application, a significant step forward for the company's treatment for inflammatory diseases. 👩🔬💡 Investor confidence has rocketed, peaking share prices at 96 cents from 33 cents in just days. This climbing momentum marks investor optimism and forecasts a potentially vibrant market future for Mesoblast. While a recent pullback in share price has occurred, the market keenly awaits the official filing with the FDA. Mesoblast's outlook remains a subject of intrigue as stakeholders look towards a potential transformative impact on the company's market value and treatment contributions. 🌟📈 Read the full analysis and insight on how Mesoblast is shaping up to potentially revolutionize the biotech landscape: https://lnkd.in/gmQygRYE #Mesoblast #StockMarket #HealthcareInnovation #Investment #Biotechnology

Thoughts on this? >> Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #healthcare #pharmaceutical #productmarketing #pharma

Thoughts on this? >> Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #productmarketing #pharma #biotech #healthcare

Join us for this webinar as our panel of experts provide a thorough understanding of how clinical trial outcomes impact biopharma company valuations. Speakers Catherine Beech MB,ChB,OBE, Amir Hefni, William Harries and Joe Hopcraft will explore the underlying drivers of these impacts, such as trial results compared to investors’ prior expectations, development phase at readout, therapy area, and trial design. https://lnkd.in/gjfAsrua #biotech

Positive clinical trial results boost Biopharma valuations, but not to the same degree as negative results lower them, and the degree of impact of valuation is influenced by the therapy area, nature of trial and other factors- this has all been robustly demonstrated in IQVIA’s recent white paper on how clinical trial results impact biopharma valuations - link below. But how can Biopharma use these insights to design trials which maximise positive value impact? Join our webinar which brings the paper’s author William Harries together with #Biopharma CEOs and IQVIA experts to discuss. https://lnkd.in/ezs77Xqe

Biotech Stocks That Have Doubled—and Could Double Again! This year has been wild for biotech stocks! Arus Biotherapeutics surged 212%, while Janux Therapeutics hit 275% in gains. Companies like Amgen and Vertex Pharmaceuticals are still standing strong with solid revenue growth and promising pipelines. With game-changing breakthroughs and more product approvals on the horizon, these stocks are worth keeping on your radar. Thinking about jumping in on the action? Let's talk about which ones you're eyeing! Are you up for winning? We know you are, so join ABET Global for your Financial Success! Join Abet Global today and trade with confidence! www.abetglobal.com #AbetGlobal #WinItWednesday #BiotechBoom #InvestingSmart #FinancialSuccess

⚕️We bring to you a NASDAQ story focused on evolving and optimizing living standards of people through bio technology innovation 🩻 Ticker (BBLG) on the NASDAQ In this episode of Capital Market Series, we bring you a NASDAQ story focused on improving the living conditions of degenerative bone problems that arise with age and/or abuse of body. With us is the President and CEO of BoneBiologics Jeff Frelick to discuss the novel research in providing a less invasive and efficient mechanisms to produce equal or better results that are currently on the market. With trials moving into the human phase in Australia, BoneBiologics is moving in the right direction for FDA approval. 🖥️ Full Episode here- https://lnkd.in/d4YNH64n In collaboration NewGen Mindset Daniel Kozel Alliance Advisors irlabs I Alyssa Barry, CPIR Johanna Gonzalez #biotech #healthcare #medical #fda #standardofliving #finance #investing #nasdaq #usa *Disclaimer:  None of the information provided in this episode should be considered investment advice and should only be viewed for informational purposes.